J 2024

Bonebridge Implantation in Treacher-Collins Syndrome With Conductive Hearing Loss-Case Report

ŠIKOLOVÁ, Soňa, Milan URÍK, Dagmar HOŠNOVÁ, Vít KRUNTORÁD, Michal BARTOŠ et. al.

Basic information

Original name

Bonebridge Implantation in Treacher-Collins Syndrome With Conductive Hearing Loss-Case Report

Authors

ŠIKOLOVÁ, Soňa, Milan URÍK, Dagmar HOŠNOVÁ, Vít KRUNTORÁD, Michal BARTOŠ and Barbora PETROVÁ

Edition

Ear, nose, & throat journal, THOUSAND OAKS, SAGE PUBLICATIONS INC, 2024, 0145-5613

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30206 Otorhinolaryngology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 1.300 in 2022

Organization unit

Faculty of Medicine

UT WoS

000945246100001

Keywords in English

Treacher-Collins Syndrome; Bonebridge Implantation; Conductive Hearing Loss

Tags

Tags

International impact, Reviewed
Změněno: 4/3/2024 09:35, Mgr. Tereza Miškechová

Abstract

V originále

The Bonebridge (BB) was the first active transcutaneous implantation system for bone conduction. The main indications are conductive or mixed hearing loss and single-sided deafness. Treacher-Collins syndrome (TCS) is a rare genetic disease that affects craniofacial development. The disorder results in deformations of facial structure including ear malformations, especially microtia and ear canal atresia. These patients suffer from conductive hearing loss. CT scans often show unfavorable temporal bone anatomy making placement of an implant difficult. For implantable hearing rehabilitation, patients may decide for conduction implants, such as a BAHA, a Ponto, a Vibrant Soundbridge, or a Bonebridge. In this case report, we present 2 patients with TCS implanted with the Bonebridge system, their audiological results, and quality of life.

Links

MUNI/A/1365/2022, interní kód MU
Name: Analýza bakteriálních původců akutního středoušního zánětu pomocí moderních sekvenačních technik
Investor: Masaryk University